ArticleMemorias do Instituto Oswaldo Cruz2022
Chagas disease control-surveillance in the Americas: the multinational initiatives and the practical impossibility of interrupting vector-borne Trypanosoma cruzi transmission.
Article in Memorias do Instituto Oswaldo Cruz, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.
- Urban vectors of Chagas disease in the American continent: A systematic review of epidemiological surveys.PLoS neglected tropical diseases · 2022Pooled it
- Targeting Amastigote and Trypomastigote Phases: Multi-Epitope Vaccine Strategy Against Trypanosoma cruzi.Biotechnology and applied biochemistry · 2026Article
- Integrated Experimental and Computational Investigation of Azobenzenoid Derivatives Against Trypanosomatid: RNA Editing Ligase 1 as a Potential Molecular Target.Acta parasitologica · 2026Article
- Multiparticulate Drug Delivery Systems Preserve the Efficacy of Reduced-Dose Intermittent Benznidazole Therapy in Experimental Chagas Disease.Research square · 2026Article
- Phenotypic Analysis of the Anti-Molecules (Basel, Switzerland) · 2026Article
- Spatial overlap of palm trees and triatomine distribution areas in Brazil.Scientific reports · 2026Article
- Economic burden of Chagas disease in Latin American countries: a population-based cost-of-illness analysis from the RAISE study.Lancet regional health. Americas · 2026Article
- Knowledge about Chagas disease among Primary Health Care professionals in a municipality located in northeastern Brazil.PLoS neglected tropical diseases · 2026Article
- Haemanthidine-Containing Alkaloid Fraction fromACS omega · 2026Article
- Analysis of the consultations on the InfoChagas digital platform.PLoS neglected tropical diseases · 2026Article
- Evaluation of Quality of Care in Chagas Disease Cardiomyopathy.Global heart · 2026Article
- New technologies for identification and surveillance of Chagas disease vectors.Revista da Sociedade Brasileira de Medicina Tropical · 2026Review
- On the juice? Trypanosoma cruzi vectorial-oral outbreak investigation in a semi-arid rural area of Brazil.Parasites & vectors · 2025Article
- High awareness, inadequate practices: a cross-sectional KAP study on Chagas disease in an endemic Venezuelan community.Tropical medicine and health · 2025Article
- Interventions for Neglected Diseases Caused by Kinetoplastid Parasites: A One Health Approach to Drug Discovery, Development, and Deployment.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Article
- Barriers to surveillance and control of re-emergence of the Chagas disease vector Triatoma infestans in Arequipa, Peru.PLoS neglected tropical diseases · 2025Article
- Triatoma dimidiata, domestic animals and acute Chagas disease: a 10-year follow-up after an eco-bio-social intervention.Parasites & vectors · 2025Article
- Prenatal Chagas disease screening in Latin America: the current policy landscape and potential utility of an expanded maternal-familialLancet regional health. Americas · 2025Review
- (In)coherence between Chagas disease policy and the experiences of those affected in Mexico: The need for a transdisciplinary approach.PLoS neglected tropical diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chagas disease (CD) still imposes a heavy burden on most Latin American countries. Vector-borne and mother-to-child transmission cause several thousand new infections per year, and at least 5 million people carry Trypanosoma cruzi. Access to diagnosis and medical care, however, is far from universal. Starting in the 1990s, CD-endemic countries and the Pan American Health Organization-World Health Organization (PAHO-WHO) launched a series of multinational initiatives for CD control-surveillance. An overview of the initiatives' aims, achievements, and challenges reveals some key common themes that we discuss here in the context of the WHO 2030 goals for CD. Transmission of T. cruzi via blood transfusion and organ transplantation is effectively under control. T. cruzi, however, is a zoonotic pathogen with 100+ vector species widely spread across the Americas; interrupting vector-borne transmission seems therefore unfeasible. Stronger surveillance systems are, and will continue to be, needed to monitor and control CD. Prevention of vertical transmission demands boosting current efforts to screen pregnant and childbearing-aged women. Finally, integral patient care is a critical unmet need in most countries. The decades-long experience of the initiatives, in sum, hints at the practical impossibility of interrupting vector-borne T. cruzi transmission in the Americas. The concept of disease control seems to provide a more realistic description of what can in effect be achieved by 2030.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.